Correlation between Receptor Activator of Nuclear Factor-κβ Ligand (RANKL), and Osteoprotegerin (OPG) with Cartilage Degradation in Rheumatoid Arthritis Patients by Hidayat, Rudy et al.
24   
ORIGINAL ARTICLE
Acta Medica Indonesiana - The Indonesian Journal of Internal Medicine
Correlation between Receptor Activator of Nuclear Factor-κβ 
Ligand (RANKL), and Osteoprotegerin (OPG) with Cartilage 
Degradation in Rheumatoid Arthritis Patients
Rudy Hidayat, Harry Isbagio, Bambang Setyohadi, Siti Setiati
Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia - Cipto Mangunkusumo Hospital, 
Jakarta, Indonesia. 
Correspondence mail: 
Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia - Cipto 
Mangunkusumo Hospital. Jl. Diponegoro no. 71, Jakarta 10430, Indonesia. email: rudy_hid@yahoo.co.id.
ABSTRAK
Tujuan: untuk menganalisis hubungan antara kadar Receptor activator of nuclear factor κβ ligand (RANKL) 
dan Osteoprotegrin (OPG) serum terhadap degradasi kartilago berdasarkan kadar cartilage oligomeric matrix 
protein (COMP) pada pasien arthritis reumatoid. Metode: studi potong lintang dilakukan pada pasien artritis 
reumatoid yang berobat ke Poliklinik Reumatologi Rumah Sakit Ciptomangunkusumo. Pasien artritis reumatoid 
baru dan lama yang didiagnosis berdasarkan kriteria yang direvisi oleh American College of Rheumatology (ACR) 
1987. Seluruh data numerik, baik data primer maupun data transformasi terdistribusi tidak normal, sehingga 
analisis bivariat menggunakan uji korelasi Spearman. Hasil: kami mengumpulkan data 60 pasien RA, sebagian 
besar dengan aktivitas penyakit yang aktif (78,3%). Metotrexate adalah obat golongan disease modifiying anti-
rheumatoid drug (DMARD) yang paling banyak digunakan, baik sebagai obat tunggal (51,7%) maupun obat yang 
dikombinasikan dengan DMARD lain (25,1%). Pada analisis bivariat didapatkan bahwa kadar RANKL serum 
(r=0,151, p=0,518), OPG serum (r=-0,085, p=0,248), dan rasio OPG/RANKL serum (r= 0,171, p = 0,191) tidak 
memiliki korelasi yang signifikan dengan kadar COMP serum. Kesimpulan: tidak terdapat korelasi yang signifikan 
antara kadar serum RANKL dan OPG dengan degradasi kartilago pada pasien artritis reumatoid.
Kata kunci: RANKL, OPG, COMP, reumatoid arthritis.
ABSTRACT
Aim: to analyze the correlation between Receptor activator of nuclear factor-κβ ligand (RANKL), Osteoprotegrin 
(OPG) serum level with cartilage oligomeric matrix protein (COMP) serum level as a marker of cartilage 
degradation in rheumatoid arthritis patients. Methods: a cross-sectional study was conducted on the subjects who 
came to the outpatient clinic of rheumatology in Cipto Mangunkusumo Hospital. Patients were diagnosed based 
on the American College of Rheumatology (ACR) 1987 revised criteria. All numerical data, both primary data and 
data transformation were not normally distributed, so we did bivariate analysis with Spearman correlation test. 
Results: we collected the data of 60 RA patients with majority of the subject had active disease activity (78.3%). 
Methotrexate was the most widely disease modifying anti-rheumatoid drug (DMARD) used, either as a single 
drug (51.7%) or in combination with another DMARD (25.1%). Bivariate analysis was revealed that RANKL, 
OPG, and OPG/RANKL serum level have no significantly correlation with COMP serum level (p=0.52; p=0.25; 
p=0.2, respectively). Conclusion: RANKL and OPG serum level, had no correlation with cartilage degradation 
in rheumatoid arthritis patients.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic 
systemic inflammatory disease that primarily 
affected the synovial tissue, accompanied by 
progressive joint destruction, bone erosion, and 
cartilage degradation.1 Bone erosion occurs 
mainly due to the inflammatory process with 
the effect of various mediators such as IL-1 
(interleukin-1), IL-6 (interleukin-6) and TNF-α 
(tumor necrosis factor-α) as the major mediator. 
Various recent studies show evidence of the role 
of RANK (receptor activator of nuclear factor-
κβ), RANKL (receptor activator of nuclear 
factor-κβ ligand) and OPG (osteoprotegerin) in 
the process of bone erosion.1-6 While the cartilage 
degradation process has been proven as a result 
of inflammatory cells and mediators that will spur 
the production of a variety of degradative enzymes 
such as MMPs (matrix metalloproteinases) and 
cathepsin.1 On the other hand, there are several 
other studies showed that the inflammatory 
process is not entirely correlated with joint 
destruction, including cartilage degradation,1,7 and 
maybe thought that the two process is a completely 
separated mechanisms.6,8
Osteoprotegerin/receptor activator of nuclear 
factor-κβ/receptor activator of nuclear factor-
κβ ligand system is also thought to have 
an essential role in the process of cartilage 
degradation, for several reasons, especially due 
to the expression of RANK, RANKL and OPG 
in chondrocyte.2,9,10 There are some studies that 
show a correlation between RANKL, OPG 
and the cartilage degradation processes,2,8,11 
although the mechanism of how OPG and 
RANKL affect the cartilage degradation process 
is still unclear. One of the theories said that 
OPG has a role to protect chondrocytes by 
binding to TRAIL (tumor necrosis factor-related 
apoptosis-inducing ligand), which has the effect 
of triggering chondrocytes apoptosis. Low OPG/
RANKL ratio will increase the chondrocytes 
apoptosis process.12 Study by Fujisaki, et al.13 
showed that the presence of RANKL under the 
influence of IL-1 will increases the expression 
of Cathepsin-K and MMP-9 which affects 
the cartilage degradation process.13 Other 
studies have been also conducted to examine 
the role of the OPG/RANK/RANKL and the 
cartilage degradation process, but they still 
give contradictory results, and all of them use 
experimental animals or cultured chondrocytes 
(in vitro studies), so it is necessary to conduct a 
study in humans, especially in RA patients.
In this study, COMP is used as a marker 
of cartilage degradation, since COMP is one 
component of the non-collagenous extracellular 
matrix and non-proteoglycans, which will 
be detected in serum if cartilage degradation 
happened and it has been known that the 
increasing of its level are not influenced by 
the level of inflammation.7,14-17 This study is 
conducted to assess the correlation between 
OPG, RANKL, OPG/ RANKL ratio, and the 
cartilage degradation process with serum level 
of COMP as marker, in RA patients.
METHODS
This is a cross sectional study, conducted at 
the outpatient clinic of rheumatology in Cipto 
Mangunkusumo Hospital. Patients were diagnosed 
based on the American College of Rheumatology 
(ACR) 1987 revised criteria and eligible with 
inclusion and exclusion criteria. The inclusion 
criteria were man or non-menopause woman 
(menstruating regularly), aged over 16 years old, 
and willing to participate in the study. Exclusion 
criteria were patients who have infectious disease 
or any inflammatory disease, has a history of 
smoking or alcohol consumption, under treatment 
with osteoporosis drugs or steroids, has a primary 
bone malignancy or metastasis, or has a chronic 
liver or kidney disease.
The subjects were chosen by consecutive 
sampling techniques, and the collected data 
were processed using SPSS 11.5 for windows. 
The result showed that all numerical data, both 
primary data and data transformation were not 
normally distributed, so we did bivariate analysis 
with Spearman correlation test. The study has 
obtained approval from the Ethics Committee of 
the Faculty of Medicine, University of Indonesia.
RESULTS
We collected data from 60 patients who were 
willing and eligible as study subjects. The entire 
study subjects were women with rheumatoid 
arthritis who have not reached menopause 
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and had regular menstrual cycles. Most of the 
subjects were in the age group 25-34 years 
(45%). The clinical characteristics of the subjects 
consisted of 78.3% of the seropositive subjects 
either by rheumatoid factor and/or anti-CCP 
examination, and the rest were seronegative. The 
disease activity has been assessed by DAS28-
LED score, and most of them had active disease 
activity (78.3%). Methotrexate was the most 
widely disease modifying anti-rheumatoid drugs 
(DMARD) used, either as a single drug (51.7%) 
or in combination with another drugs (25.1%) 
(Table 1).
Bivariate analysis was done to see the 
effect of confounding variables (ESR) to the 
independent variables (OPG, RANKL, OPG/
RANKL ratio), and the dependent variable 
(COMP), and the results on all variables showed 
a very weak correlation, and not statistically 
significant. Based on this analysis, we considered 
that ESR likely not affected the other variables 
(Table 2). Bivariate analysis was also done to 
examine the correlations between independent 
variables (OPG, RANKL, OPG / RANKL serum 
level ratio) and dependent variable (COMP 
serum level). This analysis revealed a very weak 
correlation, which was not statistically significant 
(Table 3). Evaluation of the power of this study 
showed a yield of about 80%.
DISCUSSION
In this study, we obtained 60 study subjects, 
mostly found in the 16-44 years age group. This 
Table 1. Characteristics of the study subjects
Characteristics n (%) Median (range)*
Age
 - 16-24 years 3 (5.0)
 - 25-34 years 27 (45.0)
 - 35-44 years 22 (36.7)
 - 45-54 years 8 (13.3)
Serology (rheumatoid 
factor/anti-CCP)
 - Seropositive     47 (78.3)
 - Seronegative 13 (21.7)
Disease activity (DAS28-
ESR)
 - Not active/Remision 13 (21.7) 
 - Active: 47 (78.3)
 - Low 7 (11.7)
 - Moderate 23 (38.3)
 - High 17 (28.3)
Period of illness (months) 35 (2-144)
 - <24 months 15 (25)
 - ≥24 months 45 (75)
DMARD treatment
 - MTX 31 (51.7)
 - SSZ 10 (16.7)
 - MTX+SSZ 11 (18.3)
 - MTX+Chloroquine 1 (1.7)
 - MTX+Leflunomide 1 (1.7)
 - MTX+Azathioprine 1 (1.7)
 - SSZ+ Chloroquine 3 (5.0)
 - Chloroquine 1 (1.7)
 - MTX+SSZ+ 
Chloroquine 1 (1.7)
ESR (mm/hour) 29.5 (10-100)
OPG serum level (pmol/l) 2.26 (0.14-7.91)
RANKL serum levels 
(pmol/l) 0.1 (0.02-1.27)
OPG/RANKL ratio 17.12(1.05-395.5)
COMP serum level (U/L) 8.3 (7.06-11.43)
Anti-CCP = anti-cyclic citrullinated peptide; DAS28-ESR 
= Disease Activity Score-Erythrocyte Sedimentation 
Rate; DMARD = disease modifying anti-rheumatoid drug; 
MTX = methotrexate; SSZ = sulfasalazine; ESR = 
erythrocyte sedimentation rate; OPG = osteoprotegerin; 
RANKL = Receptor Activator of Nuclear Factor-κβ Ligand; 
COMP = cartilage oligomeric matrix protein
*= not normally distributed
Table 2. Correlation between OPG, RANKL, OPG/RANKL 
ratio, COMP serum level and ESR
Variable 1 Variable 2 r* p
OPG ESR 0,159 0,226
RANKL ESR -0,057 0,665
OPG/RANKL ESR 0,092 0,483
COMP ESR 0,006 0,961
OPG=osteoprotegerin; RANKL=Receptor Activator of 
Nuclear Factor-κβ Ligand; COMP=cartilage oligomeric 
matrix protein. *=Spearman correlation test
Table 3. Correlation between OPG, RANKL, OPG/RANKL 
ratio, and COMP serum level 
Variable 1 Variable 2 r* p
OPG COMP 0,151 0,248
RANKL COMP -0,085 0,518
OPG/RANKL COMP 0,171 0,191
OPG=osteoprotegerin; RANKL=Receptor Activator of 
Nuclear Factor-κβ Ligand; COMP=cartilage oligomeric 
matrix protein. *=Spearman correlation test
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data shows a significant difference in the trend 
of prevalence by age group, compared with 
the data from epidemiological studies abroad, 
especially in Europe. Symmons, et al, reported 
that prevalence of RA patients were significantly 
higher in the older age group >45 years compared 
with those aged <45 years.18 This difference 
is likely due to variation in study population, 
while this study subjects were limited to the 
population of childbearing and who still had 
period regularly.
Data of the clinical and laboratory 
characteristics of these subjects showed that 
the majority of subjects included the RA-
seropositive (with rheumatoid factor and/or anti-
CCP positive). Assessment of disease activity 
using DAS28-ESR showed that most of them 
had active disease activity (DAS28 score >2.6), 
with domination of moderate disease activity. 
All subjects in this study had got DMARD 
therapy, and methotrexate was the most widely 
used, either as a single drug methotrexate or in 
combination with another DMARD. According to 
the 2009 European League Against Rheumatism 
(EULAR) recommendation, the first choice of 
conventional DMARD is still methotrexate, 
either as a single agent or in combination 
with another DMARD or biological agents,19 
because of efficacy and safety of this drug.20-24 
It should be noted that the majority of subjects 
still have moderate and severe disease activity, 
and most of them had a limited access to some 
conventional DMARD (such as leflunomide), 
and biological agents (such as infliximab, 
etanercept, golimumab and tocilizumab).
The result of COMP serum level examination 
of 60 subjects in this study revealed the median 
scores was 8.3 (7.06 to 11.43) U/L. We have no 
data in the normal population that could be used 
as a comparison, but we found a higher COMP 
serum level, compared with data from several 
other studies. Bender et al, and Tampoia, et al, 
showed that the mean score of COMP serum 
level in the normal population were 7.3 U/L 
and 7.4 U/L.25,26 While Elsammak, et al, found 
COMP serum level mean in the Greece normal 
population was 7.49 (4.95 to 9.56) U/L.27 It is 
a known fact that the COMP as a marker of 
cartilage degradation, especially in the case of 
RA has a very high specificity of 95% (95% CI: 
88.7-98.4), although with a lower sensitivity of 
47.6% (95% CI: 34.9-60.6).25 So, based on the 
data above, we can conclude that increasing of 
COMP serum level showed that the cartilage 
degradation is in progress.
Based on bivariate analysis, we found no 
statistically significant correlation between 
confounding variables (ESR) and all other 
variables (COMP, OPG, RANKL, and OPG/
RANKL serum level ratio). This is consistent 
with the results of other studies, such as studies 
conducted by Hamooda, et al.28 who concluded 
that there was no correlation between COMP 
serum level with ESR and level of CRP 
(C-Reactive Protein).28 Study by Lindqvist, et 
al.29 also concluded the same thing that COMP 
serum level did not correlate with any indicators 
of inflammation.29 Another study showed a 
fact that there was a significant correlation 
relationship between early elevated levels of 
serum COMP with the progression of joint 
damage that was detected two years later by the 
Larsen score, and the independent variable was 
ESR as the inflammation indicator.30 The serum 
levels of OPG and RANKL and OPG/RANKL 
ratio were not influenced by the ESR. The data 
found in this study is consistent with the results 
of other studies that the inflammatory process 
is not entirely correlated with joint destruction, 
including cartilage degradation,1,7 and both 
processes were most likely due to two separate 
difference pathological processes.6,8
Bivariate analysis were also conducted 
to examine the correlations between levels of 
serum OPG, RANKL, and the ratio of OPG/
RANKL (as independent variables) with the 
process of cartilage degradation as assessed by 
serum COMP level indicator (as the dependent 
variable). Analysis results obtained showed 
no statistically significant correlation of each 
independent variable on the dependent variable.
This study analysis could prove the existence 
of the cartilage degradation process by increasing 
the COMP serum level, in most of the RA 
patients. On the other hand, we did not obtain a 
statistically significant correlation between the 
levels of OPG, RANKL, OPG/RANKL serum (as 
independent variables) and COMP serum level 
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as cartilage degradation marker (as dependent 
variable). Based on the results of this study, it 
appears that cartilage degradation process in 
RA patients is not caused by an effects of OPG/
RANK/RANKL system, but is likely due to the 
influence of inflammatory pathways. Regarding 
the study design, we have also evaluated the 
power of this study about 80%, so the result of 
this study are not due to a lack of sample size.
CONCLUSION
We could not prove the correlation between 
RANKL, OPG serum level, and cartilage 
degradation process which was assessed based 
on COMP serum level.
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